COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,833 Articles (22,553 medRxiv, 8,280 bioRxiv)

Most recent first Previous |  Page 1793: Articles 17921-17930  | Next

Quantifying meaningful adoption of a SARS-CoV-2 exposure notification app on the campus of the University of Arizona
Masel, J., Shilen, A. N., Helming, B. H., Rutschman, J. D., Windham, G. D., Judd, M., Pogreba Brown, K., Ernst, K.
10.1101/2021.02.02.21251022 — Posted: 2021-02-03
First indication of the effect of COVID-19 vaccinations on the course of the COVID-19 outbreak in Israel
De-Leon, H., Calderon-Margalit, R., Pederiva, F., Ashkenazy, Y., Gazit, D.
10.1101/2021.02.02.21250630 — Posted: 2021-02-03
A cautionary note on recall vaccination in ex-COVID-19 subjects
Levi, R., Azzolini, E., Pozzi, C., Ubaldi, L., Lagioia, M., Mantovani, A., Rescigno, M.
10.1101/2021.02.01.21250923 — Posted: 2021-02-03 Discussion: Onsite
The role of the SwissCovid digital contact tracing app during the pandemic response: results for the Canton of Zurich
Menges, D., Aschmann, H. E., Moser, A., Althaus, C. L., von Wyl, V.
10.1101/2021.02.01.21250972 — Posted: 2021-02-03
Effect of co-infection with parasites on severity of COVID-19
Gebrecherkos, T., Gessesse, Z., Kebede, Y., Gebreegzabher, A., Tassew, G., Abdulkader, M., Ebuy, H., Desta, A., Hailu, A., Harris, V., Rinke de Wit, T., Wolday, D.
10.1101/2021.02.02.21250995 — Posted: 2021-02-03
Extremely high SARS-CoV-2 seroprevalence in a strictly-Orthodox Jewish community in the UK
Gaskell, K. M., Johnson, M., Gould, V., Hunt, A., Stone, N. R., Waites, W., Kasstan, B., Chantler, T., Lal, S., Roberts, C. h., Goldblatt, D., Eggo, R. M., Marks, M. M.
10.1101/2021.02.01.21250839 — Posted: 2021-02-03
Rapid vaccination and early reactive partial lockdown will minimize deaths from emerging highly contagious SARS-CoV-2 variants
Reeves, D. B., Bracis, C., Swan, D. A., Moore, M., Dimitrov, D., Schiffer, J. T.
10.1101/2021.02.02.21250985 — Posted: 2021-02-03 Discussion: Onsite
Elevated mucosal antibody responses against SARS-CoV-2 are correlated with lower viral load and faster decrease in systemic COVID-19 symptoms
Fröberg, J., Gillard, J., Philipsen, R., Lanke, K., Rust, J., van Tuijl, D., Bousema, T., Simonetti, E., van der Gaast-de Jongh, C., Bos, M., van Kuppeveld, F. J. M., Bosch, B. J., Nabuurs-Franssen, M., van der Geest-Blankert, N., van Daal, C., Huynen, M. A., de Jonge, M. I., Diavatopoulos, D. A.
10.1101/2021.02.02.21250910 — Posted: 2021-02-03
Deleterious effects of SARS-CoV-2 infection on human pancreatic cells
Shaharuddin, S. H., Wang, V. L., Santos, R. D., Wang, Y., Jawanda, H., Zhang, Y., Hasan, W., Garcia, G. L., Arumugaswami, V., Sareen, D.
10.1101/2021.02.01.21250846 — Posted: 2021-02-03
Colchicine use in patients with COVID-19: a systematic review and meta-analysis
Chiu, L., Chow, R., Chiu, N., Lo, C.-H., Aggarwal, R., Lee, J., Choi, Y.-G., Lam, H., Shin, H. J.
10.1101/2021.02.02.21250960 — Posted: 2021-02-03

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).